Caris Life Sciences, Inc. (CAI) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
CAI EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CAI Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 0.0% | 5.6% | -66.2% |
| 2024 | 43.4% | -62.4% | -68.4% |
| 2023 | 29.2% | -104.4% | -111.5% |
| 2022 | 31.0% | -122.2% | -124.1% |
| 2020 | 62.6% | 47.3% | 9.4% |
Download Data
Export CAI earnings history in CSV or JSON format
Free sign-in required to download data
Caris Life Sciences, Inc. (CAI) Earnings Overview
As of May 8, 2026, Caris Life Sciences, Inc. (CAI) reported trailing twelve-month net income of -$538M, reflecting -19.3% year-over-year growth. The company earned $-0.32 per diluted share over the past four quarters, with a net profit margin of -66.2%.
Looking at the long-term picture, CAI's historical earnings data spans multiple years. The company achieved its highest annual net income of $79M in fiscal 2018.
Caris Life Sciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EXAS (-$208M net income, -6.4% margin), ILMN ($853M net income, 19.6% margin), NTRA (-$309M net income, -11.2% margin), CAI has room to improve margins relative to the peer group. Compare CAI vs EXAS →
CAI Earnings vs Peers
Earnings metrics vs comparable public companies
CAI Historical Earnings Data (2003–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$538M | -90.8% | $45M | $-3.22 | -66.2% | 5.6% |
| 2024 | -$282M | +17.4% | -$257M | $-2.70 | -68.4% | -62.4% |
| 2023 | -$341M | -6.4% | -$320M | $-1.82 | -111.5% | -104.4% |
| 2022 | -$321M | -1256.8% | -$316M | $-1.57 | -124.1% | -122.2% |
| 2020 | $28M | -10.6% | $139M | $1.55 | 9.4% | 47.3% |
| 2019 | $31M | -60.5% | $130M | $1.72 | 7.4% | 31.3% |
| 2018 | $79M | +9.1% | $149M | $3.97 | 18.2% | 34.4% |
| 2017 | $72M | +1101.6% | $106M | $3.68 | 20.7% | 30.3% |
| 2016 | $6M | -77.7% | $66M | $0.31 | 2.0% | 22.4% |
| 2015 | $27M | -55.5% | $68M | $1.28 | 10.7% | 27.3% |
See CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CAI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCAI — Frequently Asked Questions
Quick answers to the most common questions about buying CAI stock.
Is CAI growing earnings?
CAI EPS fell to $-0.32, with earnings declining -19.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-538M.
What are CAI's profit margins?
Caris Life Sciences, Inc. net margin is -66.2%, with operating margin at +5.6%. Below-average margins reflect competitive or cost pressures.
How consistent are CAI's earnings?
CAI earnings data spans 2003-2025. The declining earnings trend is -19.3% YoY. Historical data enables comparison across business cycles.